Apr 9, 2020 · CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it …

CD49d is a surface subunit of the integrin heterodimer that is involved in promoting survival of the CLL cells through microenvironment derived growth signals. CD49d can be used as a reliable predictive marker of aggressive disease course and inferior survival is associated with ≥30% cells expressing CD49d by flow cytometry.

Feb 10, 2014 · In this analysis of approximately 3,000 patients, CD49d emerged as the strongest flow cytometry–based predictor of OS and TFS in CLL.

Apr 9, 2020 · CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it …

CD49d (integrin alpha 4) plays a critical role in leucocyte trafficking, activation, and survival, and also facilitates interactions between leucocytes and stromal cells found in the marrow or germinal center of lymphoid follicles via VCAM-1 and fibronectin (Rose et al, 2002).

Jan 1, 2024 · Functionally, CD49d is the α4 chain of the α4/β1 complex (CD49d/CD29) composing the very late antigen-4 (VLA-4) integrin. VLA-4 operates as a cell-cell and cell-matrix receptor by interacting with its specific ligands: VCAM-1 involved in cell-cell interactions, and FN and EMILIN1 both involved in cell-matrix interactions.

CD49d can be an activation marker, but more generally, appears to define a distinct subset of CLL. Observations linking CD49d expression to cell activation include increased frequency of CD49d+ cells in bone marrow, compared to peripheral blood, and in the CXCR4dim/CD5 bright fraction of recent emigrants from lymphoid tissues [6, 33].

Apr 25, 2016 · CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV...

Nov 2, 2023 · Here, we address the consequences of genetic B cell-specific ablation of CD49d on disease development, engraftment capacity and treatment susceptibility in a novel CLL mouse model.

Low levels of CD49d expression in newly diagnosed CLL appears to be associated with high‐risk disease displaying increased frequencies of mutated NOTCH1 and unmutated IgVH with a median treatment‐free interval of 11 months which is …